| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA900: Tixagevimab–cilgavimab for preventing COVID-19 |
|
Medicine details |
|
| Medicine name | tixagevimab/cilgavimab (Evusheld®) |
| Formulation | intramuscular injections |
| Reference number | 5101 |
| Indication | Pre-exposure prophylaxis of COVID-19 in adults who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 and who are unlikely to mount an adequate immune response to COVID-19 vaccination or for whom COVID-19 vaccination is not recommended |
| Company | AstraZeneca UK Ltd |
| BNF chapter | Respiratory system |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 25/08/2022 |
| NICE guidance | |